<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36FCE8DD-97CB-47E6-A1E8-AE17410DD826"><gtr:id>36FCE8DD-97CB-47E6-A1E8-AE17410DD826</gtr:id><gtr:name>Government of Sweden</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:department>Division of Virology</gtr:department><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36FCE8DD-97CB-47E6-A1E8-AE17410DD826"><gtr:id>36FCE8DD-97CB-47E6-A1E8-AE17410DD826</gtr:id><gtr:name>Government of Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A181FD3D-F540-4D3B-9D83-514FFD53DC26"><gtr:id>A181FD3D-F540-4D3B-9D83-514FFD53DC26</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6FC4BB73-A97A-4E27-AF06-39D123FB1570"><gtr:id>6FC4BB73-A97A-4E27-AF06-39D123FB1570</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Almond</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FDB7E018-B665-4357-883B-CDCDA5CBB63A"><gtr:id>FDB7E018-B665-4357-883B-CDCDA5CBB63A</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Stebbings</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BA7CC0D1-00D8-4823-95FE-C2C84DAF1E44"><gtr:id>BA7CC0D1-00D8-4823-95FE-C2C84DAF1E44</gtr:id><gtr:firstName>D H</gtr:firstName><gtr:surname>Ferguson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600007"><gtr:id>894DBC32-CDE3-470F-93BF-7566FF5060C5</gtr:id><gtr:title>THE ROLE OF NON-IMMUNE VACCINE RESPONSES IN PROTECTION CONFERRED BY LIVE ATTENUATED SIV</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600007</gtr:grantReference><gtr:abstractText>The World Health Organisation recognises HIV/AIDS as the number one infectious disease in the world. Doctors and scientists know that the best way to stop this disease would be to develop a vaccine to stop the 14,000 new infections with AIDS virus that occur each day worldwide. 

The difficulty is that scientists do not know whether an AIDS vaccine needs to stimulate the production of antibodies, molecules in the blood that recognise the virus and stop it from infecting new cells, or killer T cells that eliminate virus infected cells before the infection can spread further. Alternatively the vaccine may need to do something different to be fully effective. 

The team at NIBSC are studying an animal model of HIV and have found that animals vaccinated with a disabled form of the virus first are resistant to disease causing strains. This group think that events that occur within 3 weeks of vaccination are critical for the vaccine and that many of these occur in and around the gut. As a result, they will focus on unravelling these early events to enable a better AIDS vaccine to be designed and developed in the future.</gtr:abstractText><gtr:technicalSummary>In the quest for a safe, effective vaccine against HIV, many scientists believe that the potent protection conferred by live attenuated simian immunodeficiency virus (SIV) will provide pertinent insight into the responses that an AIDS vaccine will need to generate. Published work from the group at NIBSC, as well as the reports of others, have been unable to demonstrate unequivocal evidence that responses of adaptive immunity correlate with protection conferred by live attenuated SIV. Passive transfer of immune serum does not transfer protection to na?ve macaques and profound depletion of CD8+ve (cytotoxic) T cells throughout the course of vaccination does not abrogate protection. We propose to investigate whether responses apart from adaptive immunity are involved in this vaccine protection. We will characterise changes in lymphocyte subsets, activation status, and gene expression to determine, in detail, the pathogenesis of infection with a live attenuated virus SIVmacC8 in na?ve juvenile cynomolgus macaques and compare it with the pathogenesis of infection with a vigorous wild-type virus SIVmacL28 in na?ve juvenile macaques. Then we will characterise the pathogenesis of infection with SIVmacL28 in macaques that have been vaccinated with attenuated SIVmacC8 for three weeks at a time when we know that responses of adaptive immunity do not play a part in protection. For each part of the study, we will determine the kinetics of virus replication, establish the distribution of virus infected cells in 5 lymphoid tissues by in situ based techniques and determine the properties of purified infected and uninfected cells by immuno-staining and flow cytometric analysis of disaggregated tissues. The purpose of these studies will be to evaluate whether vaccination results in (i) the depletion of target cells (ii) the alteration of target cells so they are no longer capable of being infected (iii) the induction of anti-viral resistance mechanisms in infected or bystander cells not infected with the vaccine virus that prevent productive infection by wild-type virus (iv) the induction of anergy in potentially susceptible cells. As a result, we will establish the role of responses that exclude adaptive immunity in this potent vaccine protection and thus identify approaches to develop an AIDS vaccine that reproduces this protection in a safe and effective manner.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1209218</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Next Generation Sequencing</gtr:description><gtr:id>EF689A04-2BA3-4280-BDDA-F9CDD4666557</gtr:id><gtr:impact>Publication in J Clin Micro PMID: 22993180</gtr:impact><gtr:outcomeId>r4j4W452Kxe-1</gtr:outcomeId><gtr:partnerContribution>Experts in NGS, assemblies and analyses</gtr:partnerContribution><gtr:piContribution>Provision of HIV-1 RNA reference materials as a template for NGS, genome assembly and computational analysis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Mucosal immunity / virology / vaccines</gtr:description><gtr:id>203919BF-13E2-47A5-ABBF-A129F4193DCF</gtr:id><gtr:impact>Collaboration on NIH grant relating to pre-exposure prophylaxis of SIV /anti-HIV microbicide and vaccine studies leading to publication PMID 18684007</gtr:impact><gtr:outcomeId>1E06971DE95-1</gtr:outcomeId><gtr:partnerContribution>As part of the Gates foundation network of scientists partners within this international consortium have contributed both intellectually and financially with novel ideas, strategies and access to novel reagents and materials to further research initiatives Collaborative interactions on related virus research projects.</gtr:partnerContribution><gtr:piContribution>Intellectual and practical support in hosting non-human primate studies to further clinical and pre-clinical vaccine trials for HIV/AIDS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cellular and Molecular Medicine</gtr:department><gtr:description>Mucosal immunity / virology / vaccines</gtr:description><gtr:id>EE3CF08A-38EF-499A-AA8A-B135B8D6660E</gtr:id><gtr:impact>Collaboration on NIH grant relating to pre-exposure prophylaxis of SIV /anti-HIV microbicide and vaccine studies leading to publication PMID 18684007</gtr:impact><gtr:outcomeId>1E06971DE95-2</gtr:outcomeId><gtr:partnerContribution>As part of the Gates foundation network of scientists partners within this international consortium have contributed both intellectually and financially with novel ideas, strategies and access to novel reagents and materials to further research initiatives Collaborative interactions on related virus research projects.</gtr:partnerContribution><gtr:piContribution>Intellectual and practical support in hosting non-human primate studies to further clinical and pre-clinical vaccine trials for HIV/AIDS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Conditionally live attenuated SIV</gtr:description><gtr:id>7400995E-0C06-4E96-8439-05CB511A17CA</gtr:id><gtr:impact>A subsequent MRC grant has been awarded based around collaborations with this group: The role of vaccine persistence in protection conferred by live attenuated SIV (G0601201).</gtr:impact><gtr:outcomeId>18AF0F511BE-1</gtr:outcomeId><gtr:partnerContribution>Productive 2-way collaborative research with internationally recognised molecular virology broupOur collaborators have provided a novel SIV vaccine which has been trialled and evaluated at NIBSC. This has resulted in 2 distinct studies which are nearing completion and will be reported on in 2011.</gtr:partnerContribution><gtr:piContribution>Hosting of the first non-human primate study to investigate the in vivo properties of novel conditionally live attenuated SIV vaccine (SIVrtTA IAVI study)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Hepatitis C research</gtr:description><gtr:id>7860CEDA-9103-4D96-911F-D63BDC0279F9</gtr:id><gtr:impact>As part of the MRC Industrial partnership scheme a grant was awarded allowing distinct avenues of research to be undertaken.: Grant title: Restoration of pathways implicated in T cell exhaustion following HCV infection (G 0900861).</gtr:impact><gtr:outcomeId>3CCC766E36E-1</gtr:outcomeId><gtr:partnerContribution>Facilitation of industrial/academic collaborative research into the immunological and virological parameteres of HCV infection</gtr:partnerContribution><gtr:piContribution>New initiatives and research projects undertaken as result of the collaborations through the MRC Industrial partnerships scheme</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centers for Disease Control and Prevention (CDC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Office of Infectious Diseases</gtr:department><gtr:description>Vaccines and reference materials</gtr:description><gtr:id>01FA53D6-3670-425C-B27D-194D398191AC</gtr:id><gtr:impact>Publications: PMID 16989619 and another study recently accepted for publication in the Journal of Clinical Microbiology, describing the results of the international SIV RNA study</gtr:impact><gtr:outcomeId>0902EE6979C-2</gtr:outcomeId><gtr:partnerContribution>A number of distinct strands of collaborative research, including developement of international standards for SIV RNA quantification and as part of the 'Europrise' network of labs and scientists. The CDC is a key, internationally recognised laboratory in the USA which has played a central role in the collaborative study laeding to development of the SIV RNA reference panel. A key role in the collaborative study of SIV RNA reference materials</gtr:partnerContribution><gtr:piContribution>Organising centre of an international multi-centre study to develop and evaluate a panel of reference materials for the quantification of SIV RNA in plasma.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Swedish Institute for Infectious Disease Control (Smittskyddsinstitutet SMI/SIIDC)</gtr:department><gtr:description>Vaccines and reference materials</gtr:description><gtr:id>BD378C73-4136-4CF9-BC20-8127E9BB0D89</gtr:id><gtr:impact>Publications: PMID 16989619 and another study recently accepted for publication in the Journal of Clinical Microbiology, describing the results of the international SIV RNA study</gtr:impact><gtr:outcomeId>0902EE6979C-3</gtr:outcomeId><gtr:partnerContribution>A number of distinct strands of collaborative research, including developement of international standards for SIV RNA quantification and as part of the 'Europrise' network of labs and scientists. The CDC is a key, internationally recognised laboratory in the USA which has played a central role in the collaborative study laeding to development of the SIV RNA reference panel. A key role in the collaborative study of SIV RNA reference materials</gtr:partnerContribution><gtr:piContribution>Organising centre of an international multi-centre study to develop and evaluate a panel of reference materials for the quantification of SIV RNA in plasma.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HIV vaccines</gtr:description><gtr:id>01E5C5AA-E083-4404-A207-09DF5EB03DB5</gtr:id><gtr:impact>Description of innate immune responses after immunisation : Publication PMID number: 19084567</gtr:impact><gtr:outcomeId>A833451F43C-1</gtr:outcomeId><gtr:partnerContribution>Collaboration in a novel area of SIV/HIV vaccine research</gtr:partnerContribution><gtr:piContribution>Hosting of the NHP arm of an NIH funded study leading to novel observations into innate immune responses in an SIV/HIV model system</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Conditionally live attenuated SIV</gtr:description><gtr:id>0A981BBA-B298-4080-BE32-BD6FFDFA8E6A</gtr:id><gtr:impact>A subsequent MRC grant has been awarded based around collaborations with this group: The role of vaccine persistence in protection conferred by live attenuated SIV (G0601201).</gtr:impact><gtr:outcomeId>18AF0F511BE-2</gtr:outcomeId><gtr:partnerContribution>Productive 2-way collaborative research with internationally recognised molecular virology broupOur collaborators have provided a novel SIV vaccine which has been trialled and evaluated at NIBSC. This has resulted in 2 distinct studies which are nearing completion and will be reported on in 2011.</gtr:partnerContribution><gtr:piContribution>Hosting of the first non-human primate study to investigate the in vivo properties of novel conditionally live attenuated SIV vaccine (SIVrtTA IAVI study)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Swedish Institute for Infectious Disease Control (Smittskyddsinstitutet SMI/SIIDC)</gtr:department><gtr:description>Vaccines and reference materials</gtr:description><gtr:id>059302A4-10EA-4924-A723-3B4D787C22AE</gtr:id><gtr:impact>Publications: PMID 16989619 and another study recently accepted for publication in the Journal of Clinical Microbiology, describing the results of the international SIV RNA study</gtr:impact><gtr:outcomeId>0902EE6979C-1</gtr:outcomeId><gtr:partnerContribution>A number of distinct strands of collaborative research, including developement of international standards for SIV RNA quantification and as part of the 'Europrise' network of labs and scientists. The CDC is a key, internationally recognised laboratory in the USA which has played a central role in the collaborative study laeding to development of the SIV RNA reference panel. A key role in the collaborative study of SIV RNA reference materials</gtr:partnerContribution><gtr:piContribution>Organising centre of an international multi-centre study to develop and evaluate a panel of reference materials for the quantification of SIV RNA in plasma.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Medicine</gtr:department><gtr:description>Virus/ host interactions</gtr:description><gtr:id>0D4CC6E1-7125-41EC-877B-2FA201834E55</gtr:id><gtr:impact>MRC grant awarded: . 'Correlating gene expression changes and innate immune responses with protective SIV vaccination in cynomolgus macaques (G 0801172). This additional award is a direct result of the reporting grant allowing a detailed analysis of materials collected as part of this study</gtr:impact><gtr:outcomeId>BD01C5CEA06-1</gtr:outcomeId><gtr:partnerContribution>Collaboration with an internationally recognised expert in the field of retroviral restriction factors</gtr:partnerContribution><gtr:piContribution>The initial study funded by this reported grant (ie G0600007) enabled MRC funding of a further grant to analyse early gene expressions changes following live attenuated SIV vaccination. Research activities are on-going.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9CC5FAC7-C1E5-4C7F-A531-7E6E38E5B1F0</gtr:id><gtr:outcomeId>28C22CBBA670</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>830000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C892F010-FB60-48E6-A489-CFF9198AD85D</gtr:id><gtr:outcomeId>30D7D3A5FFC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>116000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AA3402ED-AAB9-4D3D-80FE-E8D2D65E8FC7</gtr:id><gtr:outcomeId>0AD254C234D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Early time-course studies of attenuated SIVmacC8, wild-type SIVmacL28 and wild-type SIVsmE660 performed has provided multiple blood and tissue samples for viral and cellular analyses</gtr:description><gtr:id>09D043B8-87EE-4CDD-9985-318FAEF08C86</gtr:id><gtr:impact>Impact of viral and cellular gene expression changes at critical sites post-infection following vaccination with live attenuated SIV. Distribution and host responses following LAV vaccination. These data are providing novel insights into the mechanism by which live attenuated virus vaccination is operating, particularly early responses to viral infection/vaccination. The role of the innate immune response has been studied and evaluated in relation to this study; the materials generated remain an invaluable study aid and have led to series of novel insights into the acute-phase responses and vaccine efficacy.</gtr:impact><gtr:outcomeId>72CC93C1D50</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Biological materials from SIVmacC8  time-course</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Refinements and improvements have been made to the model system as a result of this funding. Detailed analyses of gut-associated lymphoid tissue and other tissues have been deployed with novel extraction and cell purification protocols established.</gtr:description><gtr:id>E934527D-23D9-4FE5-94DD-D090A43365B9</gtr:id><gtr:impact>In particular the GALT analyses will allow the detailed description of the impact of attenuated and wild-type SIV replication on cell population distribution. Detailed analyses of innate responses and gene expression in this study have been highly informative in elucidating early vaccine responses.</gtr:impact><gtr:outcomeId>394FAD9B638</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Refinement of SIV model</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A bulk volume of high titre SIV + plasma was generated by in vivo studies providing a basis for a panel of SIV RNA reference materials</gtr:description><gtr:id>75DA7252-15C8-4453-930D-D83E4A9D00BC</gtr:id><gtr:impact>The first international multi-centre collaborative study was performed between centres in Europe and the USA characterising a panel of SIV RNA reference standards. Provision of these to the scientific community will facilitate the comparison of data generated between different centres in pre-clinical HIV/SIV vaccine / intervention studies. The study has been published in J Clin Micro (PMID 20427693). These materials are now widely available to the scientific community via CFAR/NIBSC (AIDS reagent repository).</gtr:impact><gtr:outcomeId>D274C2038C6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SIV RNA reference materials</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FDF939C0-57BC-48D1-B781-79A90C97B62D</gtr:id><gtr:title>A sensitive cell-based assay to measure the doxycycline concentration in biological samples.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dabefbe1c40d9b4e1d6130bef59756e"><gtr:id>2dabefbe1c40d9b4e1d6130bef59756e</gtr:id><gtr:otherNames>Kleibeuker W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>G671TgdMRh2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F62A19B3-19F6-4AF2-9550-6F8D606AF7D4</gtr:id><gtr:title>Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8).</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5AE1148F9CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8848CB29-1D44-4936-99C0-B3D79C45DE87</gtr:id><gtr:title>Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn><gtr:outcomeId>PMxv465GSza</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45A3EB2F-F2CB-4D5C-9E56-A42313FB4F30</gtr:id><gtr:title>Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52542eaf317f347220ec706e5b20b4a1"><gtr:id>52542eaf317f347220ec706e5b20b4a1</gtr:id><gtr:otherNames>Wang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>0D54A493781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A61D9CF8-DDE5-42F5-99C9-1BD6AEA57AF0</gtr:id><gtr:title>Immune Responses in the Central Nervous System Are Anatomically Segregated in a Non-Human Primate Model of Human Immunodeficiency Virus Infection.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c0283dd96b349de1ebf08f918148ca4"><gtr:id>3c0283dd96b349de1ebf08f918148ca4</gtr:id><gtr:otherNames>Tavano B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aaa598edb3896.54228721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73E09272-C5DE-4006-8868-F17E7E3249A0</gtr:id><gtr:title>Low rates of transmission of SRV-2 and STLV-I to juveniles in a population of Macaca fascicularis facilitate establishment of specific retrovirus-free colonies.</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>tZfrwSRPPfn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77C6BF17-A810-40E6-B02D-227B63169CE7</gtr:id><gtr:title>Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>VcLFBdTMKkx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91122AF7-D0B0-4D32-9ED3-7E17DB6A4977</gtr:id><gtr:title>An international collaborative study to establish a replacement World Health Organization International Standard for human immunodeficiency virus 1 RNA nucleic acid assays.</gtr:title><gtr:parentPublicationTitle>Vox sanguinis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db0f8aa3dff74a26cb87933de072153"><gtr:id>7db0f8aa3dff74a26cb87933de072153</gtr:id><gtr:otherNames>Davis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0042-9007</gtr:issn><gtr:outcomeId>hFazhgCu4T1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D0D536C-52C1-4633-B789-761F6006F354</gtr:id><gtr:title>Complete Genome Sequence of the WHO International Standard for Hepatitis B Virus DNA.</gtr:title><gtr:parentPublicationTitle>Genome announcements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be99268a8d5ba7506f852d69202e4f01"><gtr:id>be99268a8d5ba7506f852d69202e4f01</gtr:id><gtr:otherNames>Jenkins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58c93a6b890f40.65534791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2EC510F-0DB5-45B4-B794-4062461E4D29</gtr:id><gtr:title>Immunological responses and viral modulatory effects of vaccination with recombinant modified vaccinia virus Ankara (rMVA) expressing structural and regulatory transgenes of simian immunodeficiency virus (SIVmac32H/J5M).</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>FFF332D4E2E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D983309-EC6E-4D93-8794-DEC02FDB798E</gtr:id><gtr:title>Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faca3b7c173f1a1e2e76e7ff4b6d7133"><gtr:id>faca3b7c173f1a1e2e76e7ff4b6d7133</gtr:id><gtr:otherNames>Eastwood D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>c5JbnZ46X9h</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>282E451F-16FF-48C3-BFB4-18C20E31F0A8</gtr:id><gtr:title>Detection, quantification, and characterisation of HIV/SIV.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>NA3Pk2GcTmL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40612780-604B-4106-8628-2FCC7C18F073</gtr:id><gtr:title>Upregulation of TRIM5a gene expression after live-attenuated simian immunodeficiency virus vaccination in Mauritian cynomolgus macaques, but TRIM5a genotype has no impact on virus acquisition or vaccination outcome.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d601c726d34be556fecbbd27cb08186"><gtr:id>2d601c726d34be556fecbbd27cb08186</gtr:id><gtr:otherNames>Mattiuzzo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_15484_24_23152371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E5D1A36-B54E-44D3-AA94-34424DD43E62</gtr:id><gtr:title>Preparation and evaluation of the 1st international standard for the quantitation of HIV-2 RNA in plasma.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1550a602002264767ab36d5f24d82ade"><gtr:id>1550a602002264767ab36d5f24d82ade</gtr:id><gtr:otherNames>Holmes H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>D57bYYQuGoU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E79E06B-515D-4922-A8FA-942B0882AC56</gtr:id><gtr:title>Live attenuated simian immunodeficiency virus vaccination confers superinfection resistance against macrophage-tropic and neurovirulent wild-type SIV challenge.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56dee589a07365.10300975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8338B796-4488-4258-B312-66C3159DC005</gtr:id><gtr:title>Vaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28f91657807c15cd6afa1ec9392d15df"><gtr:id>28f91657807c15cd6afa1ec9392d15df</gtr:id><gtr:otherNames>Li B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>YPi9bxwWcN2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DFF0DF9-4A7D-41C7-87B9-CF64076318C6</gtr:id><gtr:title>International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce0e6cc60fcf8c388fd4f1cec0256300"><gtr:id>ce0e6cc60fcf8c388fd4f1cec0256300</gtr:id><gtr:otherNames>Ham C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>iA9TofobwF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D09235A-5B0C-43F0-B7DA-B98BD64DCBC0</gtr:id><gtr:title>Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dd8773027f8192fe964ca758e49a370"><gtr:id>3dd8773027f8192fe964ca758e49a370</gtr:id><gtr:otherNames>Berry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>58c93a6be6b1e6.00839342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1F323E5-F471-488B-AF13-4CDDFB1FFD36</gtr:id><gtr:title>Complete Genome Sequence of the WHO International Standard for HIV-2 RNA Determined by Deep Sequencing.</gtr:title><gtr:parentPublicationTitle>Genome announcements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce0e6cc60fcf8c388fd4f1cec0256300"><gtr:id>ce0e6cc60fcf8c388fd4f1cec0256300</gtr:id><gtr:otherNames>Ham C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56dee589cae1d3.67865588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C2E17AA-ECDD-43AF-9204-69482496E487</gtr:id><gtr:title>Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a999c99b6c04bf5f62563a2345ac8b61"><gtr:id>a999c99b6c04bf5f62563a2345ac8b61</gtr:id><gtr:otherNames>Findlay L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>J6Y3D46nisk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7232C52-B8C8-4E9C-8F17-D91F91AA35B4</gtr:id><gtr:title>Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b709ad3b8e7698295cad3772f08cf235"><gtr:id>b709ad3b8e7698295cad3772f08cf235</gtr:id><gtr:otherNames>Guimar?es-Walker A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>rHh77DwBjSj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CFA4716-97CF-4A6F-827B-759B183648E9</gtr:id><gtr:title>Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>cG1UEPvfm5U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>025F5951-1C9B-41CB-9EB4-DF57821CBE52</gtr:id><gtr:title>Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58c93a6c254cf7.52685058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FE864FA-74A1-4006-839E-76C24FD5C143</gtr:id><gtr:title>Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460831b3df556.07964526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A062969-6969-4C2B-8857-DEFD68C7C22D</gtr:id><gtr:title>Partial Protection by Vaccination Does Not Prevent Chronic Neuro-inflammation in an SIV Model</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546266a87157a0.28858262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94AF6B4D-4061-40FC-9BAD-09CE34D335C2</gtr:id><gtr:title>&amp;quot;Cytokine storm&amp;quot; in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242045ab417d294ec99a5f569db09bfe"><gtr:id>242045ab417d294ec99a5f569db09bfe</gtr:id><gtr:otherNames>Stebbings R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56EB60FE086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AA8A62A-1B93-42E4-BA1F-552B786DC5DF</gtr:id><gtr:title>Complete Genome Sequence of the WHO International Standard for HIV-1 RNA Determined by Deep Sequencing.</gtr:title><gtr:parentPublicationTitle>Genome announcements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df86ca6594cc3dafd0c54bd58fadccc"><gtr:id>2df86ca6594cc3dafd0c54bd58fadccc</gtr:id><gtr:otherNames>Gall A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546266ecef0916.69951455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AE57879-AF9B-42D3-8DA6-5C55720F5162</gtr:id><gtr:title>Reverse transcriptase viral load correlates with RNA in SIV/SHIV-infected macaques.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bfdc51a1b723aeeec0422e9338b8cc6"><gtr:id>7bfdc51a1b723aeeec0422e9338b8cc6</gtr:id><gtr:otherNames>Corrigan GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>95F84A63839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B574AC5-67D9-42A0-A151-785CC25A6A62</gtr:id><gtr:title>Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of medical primatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02766ea99fdc02271ba31905900e4123"><gtr:id>02766ea99fdc02271ba31905900e4123</gtr:id><gtr:otherNames>Ferguson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0047-2565</gtr:issn><gtr:outcomeId>39A5B78944B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E8A670E-EB40-4F0D-8081-DB9A2B839870</gtr:id><gtr:title>Complete Genome Sequence of a Reference Stock of Simian Immunodeficiency Virus RNA (SIVmac251/32H/L28) Determined by Deep Sequencing.</gtr:title><gtr:parentPublicationTitle>Genome announcements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be99268a8d5ba7506f852d69202e4f01"><gtr:id>be99268a8d5ba7506f852d69202e4f01</gtr:id><gtr:otherNames>Jenkins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c93a6bb233a7.56227415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>752EBD5C-002A-429C-A9EB-ED122C6DCB5B</gtr:id><gtr:title>Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d88cb86deecd8faeb7ee3b8ddbd7278c"><gtr:id>d88cb86deecd8faeb7ee3b8ddbd7278c</gtr:id><gtr:otherNames>van der Loeff MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>kbb2SZW9i4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5621E71E-AC14-4F81-B2E2-BFDA167C74E0</gtr:id><gtr:title>Diversity of TRIM5a and TRIMCyp sequences in cynomolgus macaques from different geographical origins.</gtr:title><gtr:parentPublicationTitle>Immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6ba1b9e95629587f1143575d6b64393"><gtr:id>f6ba1b9e95629587f1143575d6b64393</gtr:id><gtr:otherNames>Berry NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0093-7711</gtr:issn><gtr:outcomeId>pm_15484_24_22124667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB17DDB8-FA6A-4348-92F4-A88BA3F645E5</gtr:id><gtr:title>Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c19689ee331bac7aecb68c4f25c1a58"><gtr:id>6c19689ee331bac7aecb68c4f25c1a58</gtr:id><gtr:otherNames>Page M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>QmXhoW5Ur1n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F4E7294-D666-4F7E-8884-0561658DC743</gtr:id><gtr:title>Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ac15855ba6b861ceec45af3d9639908"><gtr:id>4ac15855ba6b861ceec45af3d9639908</gtr:id><gtr:otherNames>Das AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>AC11E463671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>214367F6-F4C2-4D29-9957-B283BDCB7C2A</gtr:id><gtr:title>Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques.</gtr:title><gtr:parentPublicationTitle>Immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0093-7711</gtr:issn><gtr:outcomeId>537BD4B9D99</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54245A08-15A7-44BB-943B-222E70A625F3</gtr:id><gtr:title>The Mhc class II DRB genotype of Macaca fascicularis does not influence infection by simian retrovirus type 2.</gtr:title><gtr:parentPublicationTitle>Tissue antigens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12e461ed539902057e92f9c71754dee6"><gtr:id>12e461ed539902057e92f9c71754dee6</gtr:id><gtr:otherNames>Mee ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0001-2815</gtr:issn><gtr:outcomeId>s7ezdXtMdLG</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600007</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>